Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GCK | P35557 | 7/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031948 | 0.78 | ALDH1A1 (0.57) | LMNAKMT2AALDH1A1GCKCYP3A4 | |
| SCHEMBL10396010 | 0.78 | ALDH1A1 (0.70) | LMNAKMT2AALDH1A1GCKCYP3A4 | |
| SCHEMBL11730615 | 0.78 | LMNA (0.59) | LMNAKMT2AALDH1A1GCKCYP3A4 | |
| SCHEMBL10395379 | 0.74 | LMNA (0.68) | LMNAKMT2AALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL10395335 | 0.73 | ALDH1A1 (0.72) | LMNAKMT2AALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL10206767 | 0.73 | LMNA (0.46) | LMNAKMT2AALDH1A1GCKCYP3A4 | |
| SCHEMBL10395407 | 0.72 | KMT2A (0.81) | LMNAKMT2AALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL10394638 | 0.72 | KMT2A (1.00) | LMNAKMT2AALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL2661906 | 0.72 | GCK (0.51) | LMNAKMT2AALDH1A1GCKCYP3A4 | |
| SCHEMBL4029532 | 0.72 | GCK (0.54) | LMNAKMT2AALDH1A1GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| EP-1663953-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030705-A9 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005030705-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | LMNA 1922/4885KMT2A 52/4885ALDH1A1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.